(111) showed that gefitinib combined with STAT3 inhibitor and anti-CD47 monoclonal antibody could reprogram TAMs and ameliorate acquired resistance to gefitinib in NSCLC. This evidence concerns the gene STAT3 and non-small cell lung carcinoma.